STOCKS TELEGRAPH

Tag: Eton Pharmaceuticals Stock

  • Eton Pharmaceuticals Sees Stock Surge Following Strategic Acquisition

    Eton Pharmaceuticals Sees Stock Surge Following Strategic Acquisition

    Eton Pharmaceuticals, Inc. (NASDAQ: ETON) shares are experiencing a notable market response following the announcement of an asset acquisition. As of the most recent market check, the stock was surging 9.43% to trade at $6.50. The announcement of an asset acquisition agreement to buy Increlex (mecasermin injection) from Ipsen S.A. corresponded with this upward rise, with deal anticipated to be completed by the end of 2024.

    ETON Strategically Concentrating on Rare Disease

    Eton Pharmaceuticals is committed to developing and distributing drugs that can dramatically enhance the quality of life for patients with rare diseases. The acquisition of the medication Increlex, which is meant for individuals with severe primary insulin-like growth factor 1 deficiency (SPIGFD), bolsters this strategic focus.

    Because of this ultra-rare illness, Increlex is an essential tool for individuals whose levels of insulin-like growth factor 1 are insufficient. The acquisition of this product enhances the company’s capacity to provide underprivileged and specialty patient populations with care.

    Raising Awareness and Making Sure Care Is Continued

    ETON has pledged to work closely with Ipsen to guarantee that patients everywhere will always have access to Increlex. This collaboration will help maintain consistency in care for those reliant on this essential treatment.

    Global Reach and Future Commercialization

    Increlex is currently approved for use in 40 territories, including the United States and the European Union. With an estimated 200 patients in the U.S. and 900-1,000 in Europe suffering from SPIGFD, Increlex remains the only treatment approved by both the FDA and EMA. Following the closing of the acquisition, Eton Pharmaceuticals will begin immediate commercialization of the product in the U.S.

    Ipsen will continue to manage international distribution for six months, ensuring a seamless transition before the company takes full responsibility. Eton plans to finance the acquisition through existing cash reserves and an expanded credit facility with SWK Holdings. Ipsen’s global sales for Increlex reached €17.3 million in 2023.

  • Eton Pharmaceuticals (ETON) Gained More Than 7% In The Last Trading Session

    Eton Pharmaceuticals (ETON) Gained More Than 7% In The Last Trading Session

    In last trading session, Eton Pharmaceuticals Inc. (ETON) stock price reached to $9.09 after a rally of +7.45%. The pharmaceutical firm specializes in the development and commercialization of novel therapies for uncommon diseases in children.

    Eton Pharmaceuticals successfully completed a deal with Diurnal Group this month for rights to commercialize ALKINDI SPRINKLE in Canada. In the United States, Eton Pharmaceuticals is currently selling the drug as an alternate for treatment of children under the age of 17 suffering with Adrenocortical Insufficiency (AI).

    CEO of Eton Pharmaceuticals, Sean Brynjelsen said that Eton has been amazed by a great deal of interest it has received from endocrinologists and caregivers in Canada since ALKINDI SPRINKLE was launched in the United States. In order to extend its relationship with DNL to include the Canadian market, Eton remained positive. The deal will allow Eton to exploit the relative success of ALKINDI SPRINKLE in the U.S. market and this will drive the company towards its ambition to become a key orphan drug manufacturer in the market.

    Martin Whitaker, CEO of Diurnal Group admitted that DNL remains fascinated by Eton’s passion and vision for ALKINDI SPRINKLE. In order to eventually introduce the medicine to young children in Canada suffering from adrenal insufficiency, where there is a substantial unmet medical need, DNL has been optimistic in expanding its partnership with Eton.

    Eton also filed a new drug application (NDA) for topiramate oral solution last month that was accepted by the U.S. Food and Drug Administration (FDA). The company had been assigned a date of August 6, 2021, by the FDA to comply with Prescription Drug User Fee Act (PDUFA).

    Topiramate is one of three oral liquid product candidates based on neurology that has been submitted to the FDA by Eton Pharmaceuticals Inc. (ETON), and all three product candidates are expected to be approved and launched this year.